Anti-angiogenesis and anticancer effects of a plasmid expressing both ENDO-VEGI151 and small interfering...

Area of Science:

• Molecular Biology
• Cancer Research
• Biotechnology

Background:

• Previous studies demonstrated that endostatin-vascular endothelial cell growth inhibitor (VEGI) fusion protein overexpression inhibits angiogenesis and exerts anticancer effects.
• Survivin is a key protein involved in cell survival and proliferation, making it a target for cancer therapy.

Purpose of the Study:

• To construct and evaluate a dual-function expression plasmid (pCDNA3.1-ENDO-VEGI151/survivin-small interfering RNA (siRNA), or pEV/si-survivin) for its anti-angiogenesis and anticancer effects.
• To assess the efficacy of pEV/si-survivin in inhibiting survivin expression and its impact on cancer cell proliferation, apoptosis, and cell cycle progression.

Main Methods:

• Construction of the pEV/si-survivin expression vector and transfection into MDA-MB-231 (cancer cells) and human umbilical vein endothelial cells (HUVECs).
• Detection of ENDO-VEGI151 and survivin expression using RT-PCR and Western blotting.
• Assessment of cell proliferation via MTT assay, and cell cycle/apoptosis analysis using flow cytometry.

Main Results:

• Successful construction and transfection of pEV/si-survivin, leading to detectable expression of ENDO-VEGI151 and survivin-siRNA in both cell lines.
• Significant reduction in survivin expression in cells treated with pEV/si-survivin.
• Inhibition of proliferation, promotion of apoptosis, and induction of cell cycle arrest in MDA-MB-231 and HUVEC cells transfected with pEV/si-survivin.

Conclusions:

• The dual-function plasmid pEV/si-survivin demonstrates in vitro efficacy in inhibiting angiogenesis and promoting tumor cell apoptosis.
• pEV/si-survivin holds potential for synergistic effects in vivo, suggesting improved tumor treatment strategies.